Zhi-Dong Zhang
Hebei Medical University
CancerInternal medicineSurgeryOncologyCellMolecular biologyChemistryApoptosisChemotherapyCapecitabineOxaliplatinAdenocarcinomaCell cycleCancer researchTransfectionFlow cytometryCell growthMedicineCell cultureBiologyGastroenterologyCancer cell
Publications 53
#1Yuan TianH-Index: 6
#2Jun WangH-Index: 171
Last. Dong WangH-Index: 1
view all 12 authors...
#1Peigang YangH-Index: 6
#2Yuan TianH-Index: 6
Last. Qun ZhaoH-Index: 13
view all 9 authors...
#1Zibo Zhang (Hebei Medical University)
#2Xiaolin Zhang (Hebei Medical University)H-Index: 11
Last. Bibo Tan (Hebei Medical University)H-Index: 15
view all 0 authors...
BACKGROUND Robotic-assisted gastrectomy has been used for treating gastric cancer since 2002. This meta-analysis was conducted to systematically evaluate the efficacy of Da Vinci robotic distal subtotal gastrectomy (RDG) or laparoscopic distal subtotal gastrectomy (LDG) in patients with gastric cancer. METHODS We conducted searches in domestic and foreign databases, and collected literature in Chinese and English on the efficacy of RDG and LDG for gastric cancer that have been published since th...
#1Yuan Tian (Hebei Medical University)H-Index: 6
#2Qun Zhao (Hebei Medical University)H-Index: 13
Last. Peigang Yang (Hebei Medical University)H-Index: 6
view all 9 authors...
Purpose. This paper is aimed at comparing the short-term efficacy of the combination of docetaxel, oxaliplatin, and capecitabine (DOX) with the combination of oxaliplatin and capecitabine (XELOX) as neoadjuvant chemotherapy regimens for the treatment of patients with resectable gastric or gastroesophageal junction adenocarcinoma. Methods. A total of 300 patients aged 20-60 years with resectable gastric or gastroesophageal junction adenocarcinoma who were evaluated with cT3/4Nany were randomly as...
#1Zihao ChenH-Index: 5
#2Yong Li (Hebei Medical University)H-Index: 10
Last. Dong Wang (Hebei Medical University)H-Index: 5
view all 10 authors...
#2Jintian Wang (Hebei Medical University)H-Index: 1
#1Zhao-Jie An (Hebei Medical University)H-Index: 1
#2Yong Li (Hebei Medical University)H-Index: 10
Last. Shao-Yi Li (Hebei Medical University)H-Index: 1
view all 8 authors...
It has been reported that the expression of Kruppel-like factor 17 (KLF17) was associated with the occurrence, development, invasion, metastasis and chemotherapy resistance of various tumors. However, the detailed mechanisms by which KLF17 promotes chemotherapy resistance in gastric cancer (GC) have not been fully investigated. In the present study, we collected the GC tissues and non-tumor tissues (matched adjacent normal tissues with corresponding GC tissues) of 60 GC patients, used qRT-PCR, W...
#1Honghai Guo (Hebei Medical University)H-Index: 2
#2Yong Li (Hebei Medical University)H-Index: 10
Last. Peigang Yang (Hebei Medical University)H-Index: 6
view all 14 authors...
This study aimed to investigate the efficacy and safety of concurrent neoadjuvant chemoradiotherapy (CRT) plus apatinib in treating locally advanced, HER2-negative, Siewert's type II-III adenocarcinoma of esophagogastric junction (AEG) patients. Thirty eligible patients were analyzed in this single-arm, open-label, phase II trial. Patients received neoadjuvant regimen as follows: two cycles of apatinib (orally, 250 mg/day on day 1-28), two cycles of capecitabine (orally, 1,000 mg/m2 twice daily ...
#1Qun Zhao (Hebei Medical University)H-Index: 13
#2Changhong Lian (Changzhi Medical College)H-Index: 1
Last. Yong Li (Hebei Medical University)H-Index: 10
view all 15 authors...
OBJECTIVES Exploring the efficacy and safety of perioperative chemotherapy on patients with AGC at different clinical and pathological stages. METHODS A phase III randomized, multicenter, trial comparing adjuvant (arm A) or perioperative S-1 plus oxaliplatin (SOX, arm B), and perioperative capecitabine plus oxaliplatin (XELOX, arm C) was initiated in T3/4, node + gastric cancer patients (unclear). Each patient received an 8-cycle chemotherapy (3 weeks for one cycle). Group arms B and C received ...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.